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ABSTRACT The objective of this study was to evaluate the clinical characteristics
and outcomes of hospitalized patients tested for Clostridium difﬁcile and determine
the correlation between pretest probability for C. difﬁcile infection (CDI) and assay
results. Patients with testing ordered for C. difﬁcile were enrolled and assigned a
high, medium, or low pretest probability of CDI based on clinical evaluation, labora-
tory, and imaging results. Stool was tested for C. difﬁcile by toxin enzyme immuno-
assay (EIA) and toxigenic culture (TC). Chi-square analyses and the log rank test were
utilized. Among the 111 patients enrolled, stool samples from nine were TC positive
and four were EIA positive. Sixty-one (55%) patients had clinically signiﬁcant diar-
rhea, 19 (17%) patients did not, and clinically signiﬁcant diarrhea could not be deter-
mined for 31 (28%) patients. Seventy-two (65%) patients were assessed as having a
low pretest probability of having CDI, 34 (31%) as having a medium probability, and
5 (5%) as having a high probability. None of the patients with low pretest probabili-
ties had a positive EIA, but four were TC positive. None of the seven patients with a
positive TC but a negative index EIA developed CDI within 30 days after the index
test or died within 90 days after the index toxin EIA date. Pretest probability for CDI
should be considered prior to ordering C. difﬁcile testing and must be taken into ac-
count when interpreting test results. CDI is a clinical diagnosis supported by labora-
tory data, and the detection of toxigenic C. difﬁcile in stool does not necessarily con-
ﬁrm the diagnosis of CDI.
KEYWORDS Clostridium difﬁcile, Clostridium difﬁcile infection, enzyme immunoassay
Clostridium difﬁcile infection (CDI) is a common and serious health care-associatedinfection; the Centers for Disease Control and Prevention estimates that there were
453,000 CDI cases and 29,300 associated deaths in the United States in 2011 (1). One
of the challenges health care facilities encounter is the complexity of accurately
diagnosing CDI (2, 3). A confounding variable that contributes to this diagnostic
challenge is that asymptomatic carriage of C. difﬁcile is common (4). Currently, available
assays can detect the presence of C. difﬁcile and/or its toxins, but there are no available
assays to diagnose CDI. The diagnosis of CDI requires the presence of appropriate
clinical signs and symptoms in combination with a positive test for toxigenic C. difﬁcile
or its toxins (5). Therefore, CDI is a clinical diagnosis that is supported by laboratory data
and/or endoscopic ﬁndings (2, 3).
While there is no true “gold standard” assay for the diagnosis of CDI, toxigenic
culture (TC) is the gold standard for detection of toxin-producing C. difﬁcile in stool and
the cell culture cytotoxicity assay (CCCA) is the gold standard for detecting free C.
difﬁcile toxin(s) in stool (6). Because these methods have a prolonged turnaround time,
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are labor-intensive, and require specialized expertise, TC and the CCCA are not currently
used as routine diagnostic methods in the United States. Commercially available assays
include enzyme immunoassays (EIAs) for toxins A and B, EIAs for glutamate dehydro-
genase, and nucleic acid ampliﬁcation tests (NAATs). NAAT sensitivity approaches that
of TC, and this methodology is now the most commonly used in the United States to
detect C. difﬁcile in stool (7).
There is increasing recognition that NAATs detect asymptomatically colonized
patients and have poor speciﬁcity for CDI and that careful patient selection for C.
difﬁcile testing would decrease false-positive tests for CDI (2, 3, 8). However, data on the
impact of clinical characteristics and pretest probability of CDI on CDI diagnosis are
scarce. Thus, the objective of this study was to evaluate the clinical characteristics and
outcomes of hospitalized patients tested for C. difﬁcile and determine the correlation
between pretest probability for CDI and assay results.
RESULTS
Demographics. Among the 111 patients enrolled in the study, stool samples from
four (3.6%) were positive by toxin EIA (EIA) and samples from nine (8.1%) were TC
positive (TC). In this sample, there were 2 EIA/TC, 7 EIA/TC, 2 EIA/TC, and 100
EIA/TC patients. Patient demographics and clinical characteristics are shown in Table
1. Potential reasons for diarrhea, other than CDI, were identiﬁed and included 22 (20%)
patients with recent chemotherapy, 18 (16%) that received a laxative within the 24 h
prior to the test request, and 15 (14%) that were receiving tube feeds. The presence of
clinically signiﬁcant diarrhea (CSD) could not be assessed in 31 (28%) patients. Among
those for which it was possible to determine the severity of diarrhea (n  80), 61 (76%)
patients experienced CSD. Among those with CSD (n  61), potential non-CDI reasons
for diarrhea included 14 (23%) patients undergoing chemotherapy and 9 (15%) who
had received a laxative in the previous 24 h (Table 2). There were signiﬁcant differences
in recent chemotherapy or tube feeds by CSD status (Table 2).
Pretest probability for CDI. Overall, 72 (65%) patients were assessed as having low
pretest probability for CDI, 34 (31%) as having a medium probability, and 5 (5%) as
having a high probability (Fig. 1). There were signiﬁcant differences (P  0.05) among
patients by pretest classiﬁcation for the following characteristics: empiric CDI treat-
ment, abdominal tenderness, leukocytosis, and toxin EIA results (Table 3). Among the
four patients (3.6%) with positive toxin EIA results, three had been rated as having a
medium probability for CDI and one had been rated as having a high probability. The
characteristics of these patients are given in Table 4. The median 90-day survival was
90 days for the low and medium groups and 76 days for the high pretest probability
of CDI (log rank, P  0.01).
Of the ﬁve patients with a high pretest probability of CDI, two (40%) of these
patients had CSD. The presence of CSD could not be determined for the other three
patients due to a lack of information from the patient or clinical team about the
patient’s stool type or stool frequency. Further examination of these ﬁve high pretest
probability patients indicate that they all had high medical acuity and/or underlying
immunosuppression, none were on laxatives, and three were on empiric treatment for
CDI prior to testing. Two patients were critically ill in the medical intensive care unit,
and four had an active hematopoietic malignancy.
One patient with a high pretest probability of CDI had a positive toxin EIA and a
negative TC result. This patient had a history of a hematopoietic malignancy with recent
chemotherapy and treatment with broad-spectrum antibiotics for health care-
associated pneumonia a month prior to the positive EIA. At the time of the positive
toxin EIA, the patient was toxic appearing, neutropenic, had diarrhea documented by
the clinical provider, and received empiric CDI treatment with metronidazole. A com-
puted tomography (CT) scan of the abdomen demonstrated diffuse bowel wall edema
of the colon. The patient was ultimately diagnosed with a perforated bowel due to
diverticulitis and associated Escherichia coli bacteremia.
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Long-term care facility 11 (10)
Outside hospital 19 (17)
Unknown 3 (3)
History of CDI in the 12 weeks before admission 5 (5)
Stool characteristics at the time of stool collection

















Unable to determine 31 (28)
Temperature of 38°C 18 (16)
White blood cell counts within 24 h of stool collection
Low (4.0) 30 (27)
Normal (4.0 to 12.0) 43 (39)
High (12.0 to 20.0) 23 (21)
Very high (20.0) 7 (6)
Not available 8 (7)




Colonic wall thickening 7 (6)
Pericolonic stranding 6 (5)
Other 34 (31)





Unable to obtain 20 (18)





Unable to obtain 12 (11)
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Toxigenic culture. C. difﬁcile was recovered in culture from the stool of 14 patients,
of which 9 were toxigenic. Four isolates were positive for tcdA, tcdB, and cdtA and cdtB.
The remaining ﬁve had only tcdA and tcdB detected. The following ﬁve different strain








Unable to obtain 12 (11)
Other explanations for diarrhea
Laxative within 24 h of test 18 (16)
Inﬂammatory bowel disease 7 (6)
Abdominal surgery in past 7 days 3 (3)
Tube feeds 15 (14)
Current chemotherapy 22 (20)
Gastrointestinal graft vs host disease 5 (5)
Other gastrointestinal infection 3 (3)
Short gut syndrome 1 (1)
aThe study population included 111 participants.
bClinically signiﬁcant diarrhea was deﬁned as 3 stools per day of Bristol stool chart type 6 or 7 or
abdominal pain plus Bristol stool chart type 6 or 7 stools.
cPatients could have more than one ﬁnding.
TABLE 2 Other reasons for diarrhea, stratiﬁed by the presence of clinically signiﬁcant
diarrhea
Variablea
No. (%) with no
clinically signiﬁcant
diarrhea (n  19)
No. (%) with
clinically signiﬁcant




Female* 9 (47) 35 (57) 9 (29)
Age
40 2 (11) 13 (21) 3 (10)
41–65 7 (37) 32 (53) 17 (55)
65 10 (53) 16 (26) 11 (36)
Nonwhite race 2 (11) 16 (26) 11 (36)
Admission location*
Home 13 (68) 49 (80) 16 (52)
Long-term care facility 0 (0) 3 (5) 8 (26)
Outside hospital 6 (32) 8 (13) 5 (16)
Unknown 0 (0) 1 (2) 2 (7)
History of CDI in previous
12 weeks
0 (0) 3 (5) 2 (7)
Other reasons for diarrhea
Laxative within 24 h 2 (11) 9 (15) 7 (23)
Inﬂammatory bowel
disease
1 (5) 3 (5) 3 (10)
Tube feeds* 0 (0) 3 (5) 12 (39)
Chemotherapy* 7 (37) 14 (23) 1 (3)
Gastrointestinal graft vs
host disease
1 (5) 2 (3) 2 (7)
Bowel prepn with
polyethylene glycol
0 (0) 1 (2) 0 (0)
Other gastrointestinal
infection
1 (5) 2 (3) 0 (0)
Other infection 0 (0) 1 (2) 0 (0)
aAn asterisk indicates a P value of 0.05.
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015/046 and 106/174, and a strain type previously characterized at Washington Uni-
versity (WU) but without a match in the European Centre for Disease Prevention and
Control (ECDC)-Cardiff reference strains named WU8 (4). Characteristics of these nine
patients are given in Table 5 and are stratiﬁed by pretest probability of CDI. Two
culture-positive patients had positive toxin EIA results and were treated for CDI. None
of the seven patients with a positive TC but negative EIA developed CDI within 30 days
after the index EIA or died within 90 days after the index toxin EIA date. Only one
TC-positive/EIA-negative patient had been started on empiric treatment with oral
metronidazole prior to culture. One patient who had a positive index EIA and positive
index TC (ribotype 027) died within 90 days of the toxin EIA.
There was no signiﬁcant difference in survival at 90 days post-EIA between patients
who were culture positive and EIA negative (n  7) and patients who were culture
negative and EIA negative (n 100) (0% EIA/TC died versus 11% EIA/TC; log rank,
P  0.37).
FIG 1 Assigned probability of CDI and toxin EIA results.
TABLE 3 Selected clinical characteristics and outcomes, stratiﬁed by pretest probability of
Clostridium difﬁcile infection
Variable







Laxatives within 24 h 12 (17) 6 (18) 0 (0)
Empiric CDI treatment 9 (13) 6 (18) 3 (60)
Able to determine presence of clinically
signiﬁcant diarrhea (n  80)
53 (74) 25 (74) 2 (40)
Clinically signiﬁcant diarrhea (n  61) 37 (51) 22 (65) 2 (40)
No clinically signiﬁcant diarrhea (n  19) 16 (22) 3 (9) 0 (0)
Unable to determine if patient had
clinically signiﬁcant diarrhea (n  31)
19 (26) 9 (27) 3 (60)
Fever 10 (14) 6 (18) 2 (40)
Leukocytosisa 13 (18) 17 (50) 0 (0)
Abdominal pain 22 (31) 20 (59) 2 (40)
Abdominal tendernessa 12 (17) 14 (41) 2 (40)
Toxigenic culture positive 4 (6) 4 (12) 1 (20)
Positive EIAa 0 (0) 3 (9) 1 (20)
CDI within 30 days after index EIA 1 (1) 0 (0) 0 (0)
Died within 90 days of EIA 5 (7) 5 (15) 3 (60)
Median survival (days)b 90 90 76
aChi-square tests indicate a P value of 0.05.
bLog rank tests indicate a P value of 0.01.
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Repeat testing. Eight patients had a repeat test ordered within 96 h of the index
test. Five of these patients were assigned a low pretest probability of CDI, two had a
medium probability, and one had a high probability. Two of these patients had an
index test which was EIA negative and TC positive (both were positive for tcdA and tcdB;
ribotypes 106/174 and 014/020). The patient with ribotype 106/174 had been assigned
a high pretest probability of CDI, had not received empiric CDI treatment, and had a
negative repeat EIA but a positive TC. The patient with ribotype 014/020 had been
assigned a medium pretest probability of CDI, had not received empiric CDI treatment,
and had a negative repeat EIA and a negative TC. None of the eight patients with repeat
TABLE 5 Positive Clostridium difﬁcile toxigenic culture resultsa
Variable
Pretest probability (no.)
Low (n  4) Medium (n  4) High (n  1)
Ribotype 027 (2) 014/020 (2) 106/174
014/020 027
WU8 015/046
Positive EIA 0 2 0
Pretest empiric CDI treatment 1 0 0
Posttest empiric CDI treatment 1 0 0
Clinical symptoms
Fever 1 0 1
Leukocytosis 1 0 0
Clinically signiﬁcant diarrhea 4 3 1
Abdominal pain 3 2 1
Abdominal tenderness 2 1 1
CT scan within previous 7 days 2b 0 0
Other reasons for diarrhea
Laxative 0 1 0
Chemotherapy 0 2 1
Developed CDI within 30 daysc 0 0 0
Died within 90 days 0 1 0
aThere were a total of 9 patients with positive TC results. Five additional patients had nontoxigenic C. difﬁcile
detected in their stool.
bCT scan ﬁndings indicated malrotation and focal pancreatitis.
cDoes not include results of index toxin EIA.
TABLE 4 Positive Clostridium difﬁcile EIA resultsa
Variable
Pretest probability (no.)b
Medium (n  3) High (n  1)
Positive toxigenic culture 1 1
Pretest empiric CDI treatment 1 1




Clinically signiﬁcant diarrhea 3 0
Abdominal pain 2 0
Abdominal tenderness 1 1
CT scan in previous 7 days 0 1c
Other reasons for diarrhea
Chemotherapy 1 0
Died within 90 days 1 1
aThere were a total of 4 positive EIA results.
bThere were 0 low pretest probability patients with positive EIA results.
cCT scan ﬁndings indicated diffuse bowel wall edema and hyperemia in colon.
Pretest Probability of CDI and C. difﬁcile EIA Journal of Clinical Microbiology
February 2017 Volume 55 Issue 2 jcm.asm.org 601
 o
n
 January 25, 2017 by W






tests within 96 h were treated for CDI or were diagnosed with CDI within 30 days,
including the patients with cultures that were positive for toxigenic C. difﬁcile. One of
the eight patients died within 90 days for reasons unrelated to CDI (oncology patient
with low pretest probability of CDI).
Only 1 out of the 111 patients had a positive C. difﬁcile EIA within the 30 days after
the index EIA and negative TC. This patient had a history of acute myeloid leukemia
and, at the time of the negative index EIA and TC tests, was classiﬁed as having a low
probability of CDI. After the index test, the patient underwent hematopoietic stem cell
transplantation (HSCT) and subsequently developed neutropenic fever and diarrhea.
Seven days after the index test, the patient had a positive EIA and TC (positive for tcdA,
tcdB, and cdtA and cdtB; PCR ribotype 126).
DISCUSSION
This study adds to the growing body of evidence that laboratory testing alone is
insufﬁcient to conﬁrm a diagnosis of CDI. Existing data suggest that many patients
tested for C. difﬁcile do not have a clinical syndrome compatible with CDI and/or have
alternative causes of diarrhea. The results of this study emphasize the tenet that a
patient’s clinical presentation should be taken into account prior to ordering, and when
interpreting, laboratory testing for C. difﬁcile.
Of the patients for whom we were able to determine diarrhea severity, only 76% had
CSD. A substantial portion of patients had other medical conditions or were on laxatives
that may have caused diarrhea at the time of the C. difﬁcile test. Similarly, in a study
designed to validate a PCR assay for C. difﬁcile, Peterson et al. found that 39% of
submitted stool samples came from patients who had fewer than three diarrheal stools
per day (9). Su et al. performed a clinical review during an evaluation of a NAAT-based
assay and found that 21% of patients no longer had diarrhea (3 loose stools within
24 h) at the time of sample collection (10). In our study, 16% were receiving a laxative
within 24 h prior to C. difﬁcile testing, including a patient receiving polyethylene glycol
in preparation for a colonoscopy. The use of laxatives prior to C. difﬁcile testing was
previously documented in studies by Buckel et al. and Dubberke et al., which noted that
up to 19% to 44% of patients tested for C. difﬁcile had documented laxative use in the
48 h prior to stool collection (5, 11).
We were unable to assess for the presence of CSD in 28% of patients due to the
absence of data from the patient or clinical team on the patient’s stool consistency or
frequency. Reasons for the lack of data included patient factors, such as the inability to
communicate due to critical illness or dementia, as well as health care worker factors,
such as a lack of documentation of clinical symptoms and stool frequency. The inability
of patients to communicate their symptoms is a limitation that clinicians face on a daily
basis, as many patients and caregivers are unable to consistently communicate due to
their medical comorbidities (for example, debilitating stroke or critical illness). Im-
proved methods for the documentation of stool consistency and frequency in the
medical health record may help clinicians accurately determine which patients should
be tested for C. difﬁcile.
In this sample, 65% of patients had a low pretest probability for CDI. Notably, none
of these patients had a positive C. difﬁcile EIA, and none of the four low-probability
patients colonized with toxigenic C. difﬁcile developed CDI-attributable complications.
Alternate causes of diarrhea were found in many of these patients, and often their
clinical presentations were not concerning for CDI after thoughtful review. This sug-
gests that C. difﬁcile testing may not be indicated in patients with a low pretest
probability for CDI.
There were some notable cases in this cohort that warrant further discussion.
One patient with a high pretest probability for CDI had a positive EIA but a negative
TC result. This patient had been on empiric CDI treatment with metronidazole prior
to testing and was ultimately diagnosed with a perforated bowel due to divertic-
ulitis and associated Escherichia coli bacteremia. A potential explanation for the
negative culture is that the metronidazole inhibited growth in culture. Alternatively,
Kwon et al. Journal of Clinical Microbiology
February 2017 Volume 55 Issue 2 jcm.asm.org 602
 o
n
 January 25, 2017 by W






the EIA was falsely positive, and all symptoms were due to diverticulitis and
bacteremia. Another patient had a positive EIA and TC 7 days after a negative index
EIA and TC. This patient had a history of acute myeloid leukemia, and at the time
of the index test, she was classiﬁed as having a low probability of CDI. Within that
7-day time period, the patient underwent HSCT and subsequently developed
neutropenic fever and diarrhea. The median incubation period from C. difﬁcile
acquisition to CDI is 7 days (12). Given the continued hospital exposure and
immunocompromised state, it is likely that this patient acquired C. difﬁcile and
developed CDI after the negative index test.
None of the seven patients with a negative index EIA but positive TC developed CDI
within 30 days after the index EIA or died within 90 days after the index test. Of the
eight patients who had a repeat test ordered within 96 h of a negative index test, two
patients had an index test which was EIA negative and TC positive. Neither had received
empiric CDI treatment, both had negative repeat EIAs, one had a positive repeat TC,
and neither was diagnosed with CDI or died within 30 days of the index EIA. Although
patients may have clinical syndromes concerning for CDI, they may be colonized with
C. difﬁcile and not have actual CDI. These ﬁndings are consistent with prior literature;
Polage et al. demonstrated that C. difﬁcile-attributable complications are rare among
patients with a negative C. difﬁcile toxin EIA (13). In another study, Polage et al.
demonstrated that presentation and CDI-related complications were no different in
patients that had negative toxin EIA and PCR tests than they were in patients with
negative toxin EIA and positive PCR tests (14).
There are several limitations to this study. First, it was relatively small and it was
conducted over a short time frame at a single institution; a larger study with a longer
assessment period would allow for more robust statistical analyses of CDI-related
outcomes and mortality. Second, the pretest CDI probabilities were assigned by a single
physician. As we have emphasized, CDI is a diagnosis that relies heavily on clinical
judgment, and our results may have been biased by the assessments of one physician’s
judgment. Outcomes based on CDI probability suggest that this is not the case; median
survival was shortest in the high pretest probability group (90, 90, and 76 days in the
low, medium, and high probability groups, respectively). In the current investigation,
we did not perform a molecular test for C. difﬁcile; however, previous studies have
shown that when PCR is used to detect C. difﬁcile in hospitalized patients with diarrhea,
the sensitivity approaches that of TC (7, 15).
This study provides additional emphasis on the importance of patients’ clinical
symptoms for the interpretation of C. difﬁcile diagnostic assays. Assignment of a pretest
probability for CDI at the time of testing is a novel approach for assessing the impact
of the overall clinical picture on the interpretation of C. difﬁcile assay results. As we
assessed patients in real-time and did not exclude patients who could not communi-
cate their stool characteristics or frequency, this study is generalizable to the circum-
stances that clinicians encounter on a daily basis. Data regarding the patient’s symp-
toms and clinical exam were collected prospectively; we were not limited by
retrospective medical record data. Given the prospective data collection, we were able
to collect a more complete record of a patient’s stool characteristics, as often diarrhea
is incompletely captured in a medical chart. Further prospective studies of this nature
would be of value.
Clinicians and health care facilities continue to search for a C. difﬁcile test that is
simultaneously rapid, sensitive, and speciﬁc for CDI. Certainly, more research is needed
on diagnostic methods for CDI, especially given the important consideration of asymp-
tomatic colonization. However, perhaps the difﬁculties encountered in CDI diagnosis
are less a failure of diagnostic technology than an overreliance on diagnostic tests and
an underreliance on clinical assessments. Moving forward, methods and guidelines to
diagnose CDI that couple laboratory-based C. difﬁcile detection with clinical assess-
ments need to be developed.
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Setting. This prospective cohort study was performed at Barnes-Jewish Hospital, a 1,250-bed tertiary
care hospital in St. Louis, MO, from August to October 2014. The study was part of a quality-improvement
initiative to improve C. difﬁcile testing practices. The Washington University (WU) Human Research
Protection Ofﬁce approved publication of the results of this quality improvement project. Inpatients who
were 18 years old were eligible if they had a C. difﬁcile EIA ordered.
Clinical evaluation. Consecutive inpatients with C. difﬁcile testing ordered were approached to
participate. A physician (J.H.K.) interviewed patients and evaluated their symptoms, stool characteristics
and frequency, and performed an abdominal exam. Stool characteristics were assessed with the Bristol
stool scale, and clinically signiﬁcant diarrhea (CSD) was deﬁned as 3 Bristol type 6 or 7 stools per day
or abdominal pain plus Bristol type 6 or 7 stools (5, 16, 17). If the patient and/or clinical team was unable
to provide information regarding the stool type or frequency, CSD was documented as “unable to be
determined.” Additional data obtained included patient demographics, vitals, antibiotics, laxatives
(docusate, senna, polyethylene glycol, lactulose, enemas), tube feeds, CDI history, imaging, and white
blood cell counts (WBC). Patients were then assigned a high, medium, or low pretest probability of CDI.
This rating was assigned prior to the availability of the patients’ C. difﬁcile testing results. The pretest
probability for CDI was determined based on a combination of the patient’s stool history, clinical signs,
symptoms, abdominal exam, laboratory test results, and radiology ﬁndings. If there were other more
probable causes of diarrhea, such as the presence of a laxative or underlying gastrointestinal pathology
(mucositis related to chemotherapy), this was also taken into consideration. If CSD was unable to be
determined, all other data gathered was used to assist in the determination of pretest probability. For
example, if CSD was unable to be determined but the patient had other exam, laboratory, and
radiographic ﬁndings highly consistent with CDI, the patient would be assigned a high pretest proba-
bility for CDI.
Laboratory testing for C. difﬁcile. Patients’ stool samples were submitted to the clinical laboratory
for testing with the TechLab Tox A/B II EIA (Blacksburg, VA); testing was rejected on formed stools (3).
If available, remnant stool was frozen at 80°C. Culture for C. difﬁcile was performed as previously
described (18). Brieﬂy, an aliquot of stool was heated at 80°C for 10 min followed by inoculation into
cycloserine-cefoxitin mannitol broth with taurocholate and lysozyme (Anaerobe Systems, Morgan Hill,
CA). Colonies resembling C. difﬁcile were identiﬁed using matrix-assisted laser desorption ionization–time
of ﬂight (MALDI-TOF) mass spectrometry (MS) using the Vitek MS platform (bioMérieux, Durham, NC) (19).
Isolates were evaluated for the presence of tcdA, tcdB, and binary toxin genes (cdtA and cdtB) by
multiplex PCR (4, 20, 21) and were characterized by PCR ribotyping (21).
Statistical analysis. Patients’ assigned pretest probability of CDI based on clinical signs and
symptoms was compared with the toxin EIA results and TC results. Chi-square analyses and the log rank
test were used for analyses (SPSS version 21; IBM Statistics, Armonk, NY).
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